<?xml version="1.0" encoding="utf-8"?>
			
			<rss version="2.0" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:cc="http://web.resource.org/cc/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">

			<channel>
			<title>melissaweber Blog</title>
			<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber</link>
			<description>melissaweber Blog</description>
			<language>en-us</language>
			<pubDate>Wed, 22 May 2013 09:03:02 -0700</pubDate>
			<lastBuildDate>Thu, 29 Apr 2010 12:41:00 -0700</lastBuildDate>
			<generator>BlogCFC</generator>
			<docs>http://blogs.law.harvard.edu/tech/rss</docs>
			<managingEditor>moderator@curetoday.com (moderator)</managingEditor>
			<webMaster>moderator@curetoday.com (moderator)</webMaster>
			<itunes:subtitle></itunes:subtitle>
			<itunes:summary></itunes:summary>
			<itunes:category text="Technology" />
			<itunes:category text="Technology">
				<itunes:category text="Podcasting" />
			</itunes:category>
			<itunes:category text="Technology">
				<itunes:category text="Tech News" />
			</itunes:category>
			<itunes:keywords></itunes:keywords>
			<itunes:author></itunes:author>
			<itunes:owner>
				<itunes:email>moderator@curetoday.com</itunes:email>
				<itunes:name></itunes:name>
			</itunes:owner>
			<itunes:image href="http://www.curetoday.com/assets/images/placeholder.gif" />
			<image>
				<url>http://www.curetoday.com/assets/images/placeholder.gif</url>
				<title>melissaweber Blog</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber</link>
			</image>
			<itunes:explicit>no</itunes:explicit>
			
			
			
			
			
			<item>
				<title>FDA approves first vaccine to treat cancer</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2010/4/29/FDA-approves-first-vaccine-to-treat-cancer</link>
				<description>
				
				
				After decades of research, the first vaccine to treat cancer has won approval from the Food and Drug Administration. In a milestone decision, the FDA today approved Provenge (sipuleucel-T) for men with metastatic prostate cancer that is resistant to ...
				
				
				</description>
						
				
				<category>Featured</category>				
				
				<category>News</category>				
				
				<category>Treatment</category>				
				
				<pubDate>Thu, 29 Apr 2010 12:41:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2010/4/29/FDA-approves-first-vaccine-to-treat-cancer</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>Tarceva approved for new use in lung cancer</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2010/4/17/Tarceva-approved-for-new-use-in-lung-cancer</link>
				<description>
				
				
				Patients with advanced non-small cell lung cancer now have the option of receiving a targeted drug immediately after chemotherapy--before the disease worsens.

Late Friday, the Food and Drug Administration approved Tarceva (erlotinib) as maintenanc...
				
				
				</description>
						
				
				<category>Diagnosis</category>				
				
				<category>News</category>				
				
				<category>General</category>				
				
				<category>Treatment</category>				
				
				<pubDate>Sat, 17 Apr 2010 23:59:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2010/4/17/Tarceva-approved-for-new-use-in-lung-cancer</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>Tips for traveling with a child who has cancer</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2010/3/17/Tips-for-traveling-with-a-child-who-has-cancer</link>
				<description>
				
				
				With spring break upon us and summer vacation not too far behind, you&apos;re likely making plans for your next family getaway. Whether it&apos;s a day trip to a nearby amusement park or a week at the beach, traveling can be complicated when you have a child w...
				
				
				</description>
						
				
				<category>General</category>				
				
				<category>Caregiving</category>				
				
				<pubDate>Wed, 17 Mar 2010 10:53:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2010/3/17/Tips-for-traveling-with-a-child-who-has-cancer</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>What&apos;s different about the new prostate cancer screening guidelines?</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2010/3/3/Whats-different-about-the-new-prostate-cancer-screening-guidelines</link>
				<description>
				
				
				With its first update in almost a decade, the American Cancer Society today released revised guidelines for prostate cancer screening. Although some recommendations haven&apos;t changed--most notably, they still don&apos;t support routine screening for prostat...
				
				
				</description>
						
				
				<category>Diagnosis</category>				
				
				<category>News</category>				
				
				<category>General</category>				
				
				<pubDate>Wed, 03 Mar 2010 15:34:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2010/3/3/Whats-different-about-the-new-prostate-cancer-screening-guidelines</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>Rituxan approved for most common type of leukemia</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2010/2/19/Rituxan-approved-for-most-common-type-of-leukemia</link>
				<description>
				
				
				Last night, the Food and Drug Administration announced its approval of Rituxan (rituximab) in combination with fludarabine and cyclophosphamide (FC) for the treatment of CD20-positive chronic lymphocytic leukemia. The combination can be given to CLL ...
				
				
				</description>
						
				
				<category>News</category>				
				
				<category>General</category>				
				
				<category>Treatment</category>				
				
				<pubDate>Fri, 19 Feb 2010 08:49:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2010/2/19/Rituxan-approved-for-most-common-type-of-leukemia</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>American Idol-esque talent competition for young adult survivors gets under way</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2010/1/26/American-Idolesque-talent-competition-for-young-adult-survivors-gets-under-way</link>
				<description>
				
				
				Instead of American Idol or So You Think You Can Dance, young musicians and dancers with cancer now have a competition of their own.

Vital Options has launched Surviving Idol: Young Adults with Cancer Expressing Themselves in support of National Y...
				
				
				</description>
						
				
				<category>Survivorship</category>				
				
				<category>News</category>				
				
				<category>General</category>				
				
				<pubDate>Tue, 26 Jan 2010 16:32:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2010/1/26/American-Idolesque-talent-competition-for-young-adult-survivors-gets-under-way</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>New test available that predicts risk of colon cancer recurrence</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2010/1/21/New-test-available-that-predicts-risk-of-colon-cancer-recurrence</link>
				<description>
				
				
				Genomic Health announced today that its Oncotype DX colon cancer test to determine the risk of recurrence in patients with stage 2 colon cancer is now commercially available. 

The colon cancer test looks at the activity of 12 genes in the patient&apos;...
				
				
				</description>
						
				
				<category>Diagnosis</category>				
				
				<category>News</category>				
				
				<category>General</category>				
				
				<category>Treatment</category>				
				
				<pubDate>Thu, 21 Jan 2010 16:36:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2010/1/21/New-test-available-that-predicts-risk-of-colon-cancer-recurrence</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>Help Drew Carey give his money to the Lance Armstrong Foundation</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2010/1/20/Help-Drew-Carey-give-his-money-to-the-Lance-Armstrong-Foundation</link>
				<description>
				
				
				Drew Carey really wants to give the Lance Armstrong Foundation a million bucks. Last fall, the actor and host of The Price Is Right said he would donate $1 million to LAF if his @DrewFromTV Twitter account reached a million followers before the ball ...
				
				
				</description>
						
				
				<category>News</category>				
				
				<category>General</category>				
				
				<pubDate>Wed, 20 Jan 2010 16:35:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2010/1/20/Help-Drew-Carey-give-his-money-to-the-Lance-Armstrong-Foundation</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>Curetoday.com&apos;s most-read articles and blogs of 2009</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2009/12/31/Curetodaycoms-mostread-articles-and-blogs-of-2009</link>
				<description>
				
				
				So, which stories caught your eye during the past year? Based on the top 10 most popular articles and blogs on curetoday.com, you sampled a little bit of everything--nutrition, treatment, finances, end of life, and late effects.

We followed your c...
				
				
				</description>
						
				
				<category>Nutrition</category>				
				
				<category>Survivorship</category>				
				
				<category>News</category>				
				
				<category>General</category>				
				
				<category>Treatment</category>				
				
				<pubDate>Thu, 31 Dec 2009 10:25:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2009/12/31/Curetodaycoms-mostread-articles-and-blogs-of-2009</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>Is Treanda a better mate to Rituxan than CHOP?</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2009/12/7/Is-Treanda-a-better-mate-to-Rituxan-than-CHOP</link>
				<description>
				
				
				Treanda (bendamustine) may soon replace CHOP as the chemotherapy buddy to Rituxan (rituximab) for patients with advanced follicular, indolent, and mantle cell lymphoma who are getting first-line treatment, following research presented today at the Am...
				
				
				</description>
						
				
				<category>News</category>				
				
				<category>Treatment</category>				
				
				<pubDate>Mon, 07 Dec 2009 15:28:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2009/12/7/Is-Treanda-a-better-mate-to-Rituxan-than-CHOP</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>More frequent dose of Rituxan fails to show benefit</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2009/12/7/More-frequent-dose-of-Rituxan-fails-to-show-benefit</link>
				<description>
				
				
				The standard schedule of giving Rituxan every three weeks, as opposed to every two weeks, is still the best option for older patients with diffuse large B-cell lymphoma, according to research presented today at ASH&apos;s annual meeting.

Early analysis...
				
				
				</description>
						
				
				<category>News</category>				
				
				<category>Treatment</category>				
				
				<pubDate>Mon, 07 Dec 2009 13:44:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2009/12/7/More-frequent-dose-of-Rituxan-fails-to-show-benefit</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>Four drugs may be better than three in older myeloma patients</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2009/12/6/Four-drugs-may-be-better-than-three-in-older-myeloma-patients</link>
				<description>
				
				
				A four-drug combo with Velcade (bortezomib) followed by maintenance therapy resulted in better response rates and less neuropathy compared with the standard three-drug Velcade combo in newly diagnosed multiple myeloma patients who are over age 65.
...
				
				
				</description>
						
				
				<category>News</category>				
				
				<category>Treatment</category>				
				
				<pubDate>Sun, 06 Dec 2009 21:02:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2009/12/6/Four-drugs-may-be-better-than-three-in-older-myeloma-patients</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>Coping easier for patients with advance care plans</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2009/12/6/Coping-easier-for-patients-with-advance-care-plans</link>
				<description>
				
				
				Advanced care planning--that is, having a living will and a designated health care proxy--helps patients with blood cancers better cope, according to research presented today at the American Society of Hematology&apos;s annual meeting in New Orleans.

R...
				
				
				</description>
						
				
				<category>News</category>				
				
				<category>General</category>				
				
				<pubDate>Sun, 06 Dec 2009 17:15:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2009/12/6/Coping-easier-for-patients-with-advance-care-plans</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>Online tool helps narrow down treatment options for breast cancer</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2009/11/19/Online-tool-helps-narrow-down-treatment-options-for-breast-cancer</link>
				<description>
				
				
				My Breast Cancer Coach is pretty straightforward: Answer a handful of questions about your type of breast cancer and in return you get a personalized report of treatment options to talk over with your doctor.

The online tool has been available for...
				
				
				</description>
						
				
				<category>Diagnosis</category>				
				
				<category>Treatment</category>				
				
				<pubDate>Thu, 19 Nov 2009 15:31:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2009/11/19/Online-tool-helps-narrow-down-treatment-options-for-breast-cancer</guid>
				
			</item>
			
		 	
			
			
			<item>
				<title>Want to know the top cancer advances for 2009?</title>
				<link>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex//melissaweber/2009/11/9/Want-to-know-the-top-cancer-advances-for-2009</link>
				<description>
				
				
				Each year, the American Society of Clinical Oncology releases a report that pinpoints the top advances in cancer treatment, prevention and screening. This year, ASCO identified 15 key advances in four areas. (The advances were not ranked.) 

Here&apos;s...
				
				
				</description>
						
				
				<category>Diagnosis</category>				
				
				<category>News</category>				
				
				<category>General</category>				
				
				<category>Treatment</category>				
				
				<pubDate>Mon, 09 Nov 2009 07:29:00 -0700</pubDate>
				<guid>http://www.curetoday.com/index.cfm/fuseaction/blog.showIndex/melissaweber/2009/11/9/Want-to-know-the-top-cancer-advances-for-2009</guid>
				
			</item>
			
		 	
			</channel></rss>